Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term antitumor-activity. Found 24 abstracts

no pagination
Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Rev Precis Me. 2018 May;3(3):197-204.   PMCID: PMC6366666
Patson B, Cohen RB, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology. 2012 Feb;8(2):259-70.   PMCID: not NIH funded
Vadakara J, Pro B. Targeting CD30 in Anaplastic Large Cell Lymphoma. Current Hematologic Malignancy Reports. 2012 Dec;7(4):285-91.   PMCID: Not NIH fund
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 May;121(2):303-8.   PMCID: PMC3081894
Gupta S, Engstrom PF, Cohen SJ. Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer. 2011 Dec;10(4):298-309.   PMCID: NIHMS329029
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biology & Therapy. 2010 Oct;10(7):658-64.   PMCID: PMC3093809
Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 2010 Jul;66(2):287-94.   PMCID: PMC2873145 [Available on 2011/1/1]
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics. 2010 Aug;9(8):2411-22.   PMCID: PMC2941981 [Available on 2011/8/1]
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies - Potential clinical applications for tumor immunotherapy. Current Opinion in Investigational Drugs. 2010 Dec;11(12):1378-86.   PMCID: not NIH funded
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G(1) Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. Journal of Clinical Oncology. 2010 Feb;28(5):780-7.   PMCID: PMC2834394
Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha. Cancer. 2009 Aug;115(16):3651-60.   PMCID: not NIH funded
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009 Sep;27(27):4462-8.   PMCID: not NIH funded
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Jun;295(21):2516-24.
Scallon BJ, Snyder LA, Anderson GM, Chen QM, Yan L, Weiner LM, Nakada MT. A review of antibody therapeutics and antibody-related technologies for oncology. JOURNAL OF IMMUNOTHERAPY. 2006 Jul;29(4):351-64.
Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. SEMINARS IN ONCOLOGY. 2005 Jan;32(6):S23-S29.
Langer CJ. Dilemmas in management: The controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax (TM)). The oncologist. 2004 Jan;9(4):398-405.
Mu ZM, Hachem P, Agrawal S, Pollack A. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. The Prostate. 2004 Aug;60(3):187-96.
Damjanov N, Meropol NJ. Oral therapy for colorectal cancer: How to choose. Oncology-New York. 2000 Jun;14(6):799-807.
Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C. Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of Oncology. 1999 Mar;10(3):339-44.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term antitumor-activity

antitumor-activity tyrosine kinase inhibitor cancer endothelial growth-factor phase-ii trial metastatic colorectal-cancer in-vitro in-vivo cell lung-cancer efficacy interferon-alpha solid tumors monoclonal-antibody Oncology angiogenesis expression therapy phase-ii trial bevacizumab phase-iii trial lung-cancer renal-cell carcinoma inhibitor factor receptor sunitinib signaling pathways randomized-trial prodrug gene-expression CD30 Anaplastic large cell lymphoma-SGN-35-Brentuximab-Vedotin-MMAE-T-cell lymphoma ribosome-inactivating proteins placebo 1994 audhry a-anticancer research-v14-p2085 dihydropyrimidine dehydrogenase-activity protooncogene human igg1 conjugate oral angiogenesis inhibitor raf kinase 7 days contrast-enhanced mri growth Research & Experimental Medicine diastolic blood-pressure anti-cd20 monoclonal-antibody apoptosis somatostatin plus gemcitabine phase I dose-escalation hypoxia-inducible factor-1 k-ras activation zk ii malignant carcinoid-syndrome zk-222584 ptk transcription factor foxp3 VEGF mediated apoptosis Foxp3 Cancer-GITR-immunotherapy-regulatory T-cell death receptor dr4 human colon-cancer brentuximab vedotin sgn-35 apoptosis-inducing ligand 5-fluorouracil topotecan 5-ethynyluracil 776c85 induced tnf receptor gi147211 thiol reductase gilt human angiogenin tumor angiogenesis interleukin-2 pathway 1992 audhry a-cancer research-v52-p1006 wild-type Targeted therapy Neuroendocrine tumors 1993 audhry a-acta oncologica-v32-p107 tic10 gastrointestinal stromal tumors Cisplatin combination immunotherapy su11248 angiogenesis inhibitor uterine cervix costimulatory receptor monoclonal-antibody c225 tyrosine kinase camptothecin 1st-line treatment signal-transduction pathway kinases uracil days on 1995 ristofori g-molecular endocrinology-v9-p1760 performance status anti-cd30 mammalian target trail epigenetics erlotinib growth-factor General & Internal Medicine mouse gitr chemotherapy Immunology genetics cytochrome-c release 2-stage designs interferon t-lymphocytes vascular endothelial growth factor Cervical cancer growth-factor receptor gefitinib p53 protein accumulation biochemical modulation cooperative-oncology-group small-molecule onc201 regulatory t-cells scid mice GG211 xenografts complement activation AG-013736 prognostic-factors paclitaxel met phase i camptothecin analogues histone infusion fluorouracil gynecologic-oncology-group carcinoma in-vivo activities mTOR castration human cancer-cells topoisomerase I inhibitors protein malignant-tumors deacetylase inhibitors refractory solid tumors thymidine phosphorylase tumor-suppressor fc-gamma-ri necrosis-factor-alpha
Last updated on Friday, January 03, 2020